Determination of tumor markers in serum. Pitfalls and good practice

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 12, 2001, Pages 1227-1233

  Basuyau, J P ^a   Leroy, M ^a   Brunelle, P ^a  

^a CENTRE HENRI BECQUEREL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CA 125 ANTIGEN; CA 19-9 ANTIGEN; IMMUNOGLOBULIN ANTIBODY; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TUMOR MARKER;

ADULT; AGED; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; GOOD LABORATORY PRACTICE; HUMAN; KINETICS; MALE; MATERIALS HANDLING; METHODOLOGY; NORMAL VALUE; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ANTIBODIES; CA-125 ANTIGEN; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOLOGIC TECHNIQUES; KINETICS; LABORATORIES, HOSPITAL; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNOLOGY, MEDICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 0035667175     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.197     Document Type: Review

References (23)

1. Difficultés analytiques de l'exploration thyroïdienne en pratique quotidienne
2. Guide de Bonne Exécution des Analyses de biologie médicale
3. Carcinoembryonic antigen
4. Antigenic sites in ACE
5. Thyroglobulin and anti-thyroglobulin autoantibodies. Methods of enzymatic analysis
6. Highly sensitive immunoradiometric assay for thyroglobulin with minimal interference from autoantibodies
7. Value of HAMA. Determination in clinical practice An overview
8. Interférences des anticorps antiimmunoglobulines, un poison pour tous les dosages immunologiques. II. Interférences, mise en évidence et suppression
9. Apport du CA 15.3 en cancérologie mammaire
10. Post treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate
11. A new approach for clinical biological assay comparison and standardization: Application of principal component analysis to a multicenter study of twenty-one ACE immunoassay kits
12. The Second Stanford Conference on International Standardization of PSA
13. Elevation of CA 125 in patients with benign and malignant ascites
14. The evaluation of CA 19.9 antigen in the early detection of pancreatic cancer
15. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer
16. Serum PSA in a community-based population of healthy men. Establishment of age-specific reference ranges
17. Comparison of CA 125 assays with abdominopelvic computed tomodensitometry and transvaginal ultrasound in monitoring ovarian cancer
18. Risk and prognostic factors in trophoblastic neoplasma
19. A prognostic factor-based staging system for metastatic germ cells cancers. IGCCC Collaborative Group
20. Localized prostate cancer: Use of serial PSA measurements during radiation therapy
21. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring
22. Valeur pronostique de la demi - Vie initiale du CA 125 au cours de la chimiothérapie d'induction chez 62 patientes porteuses de tumeurs épithéliales ovarienne stades III-IV
23. Fédération Nationale des Centres de Lutte Contre le Cancer - Standards, Options et Recommandations (SOR): Marqueurs tumoraux sériques du cancer du sein